Technical Analysis for SPPI - Spectrum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 11.71 0.09% 0.01
SPPI closed up 0.09 percent on Friday, February 15, 2019, on 49 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Mar 5

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical SPPI trend table...

Date Alert Name Type % Chg
Feb 15 Stochastic Sell Signal Bearish 0.00%
Feb 15 Bollinger Band Squeeze Range Contraction 0.00%
Feb 15 Upper Bollinger Band Walk Strength 0.00%
Feb 15 Weak + Overbought Other 0.00%
Feb 15 BB Squeeze + Upper Band Touch Range Contraction 0.00%
Feb 15 Outside Day Range Expansion 0.00%
Feb 15 Overbought Stochastic Strength 0.00%
Feb 15 Upper Bollinger Band Touch Strength 0.00%
Feb 14 Bollinger Band Squeeze Range Contraction 0.09%
Feb 14 NR7 Range Contraction 0.09%

Older signals for SPPI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
Medicine Biotechnology Health Cancer Chemotherapy Radiation Prostate Cancer Solid Tumor Osteosarcoma Cancer Therapy Non Muscle Invasive Bladder Cancer Oncology Products Treating Cancer Neutropenia Ozarelix
Is SPPI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.29
52 Week Low 6.22
Average Volume 1,466,148
200-Day Moving Average 16.5611
50-Day Moving Average 10.7048
20-Day Moving Average 11.158
10-Day Moving Average 11.36
Average True Range 0.5753
ADX 24.54
+DI 23.3164
-DI 11.367
Chandelier Exit (Long, 3 ATRs ) 10.2841
Chandelier Exit (Short, 3 ATRs ) 11.8259
Upper Bollinger Band 11.8667
Lower Bollinger Band 10.4493
Percent B (%b) 0.89
BandWidth 12.702993
MACD Line 0.2485
MACD Signal Line 0.1741
MACD Histogram 0.0744
Fundamentals Value
Market Cap 922.57 Million
Num Shares 78.8 Million
EPS -1.00
Price-to-Earnings (P/E) Ratio -11.71
Price-to-Sales 11.56
Price-to-Book 7.68
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.31
Resistance 3 (R3) 12.33 12.16 12.21
Resistance 2 (R2) 12.16 12.00 12.15 12.18
Resistance 1 (R1) 11.93 11.91 11.85 11.91 12.14
Pivot Point 11.76 11.76 11.71 11.75 11.76
Support 1 (S1) 11.53 11.60 11.45 11.51 11.28
Support 2 (S2) 11.36 11.51 11.35 11.24
Support 3 (S3) 11.13 11.36 11.21
Support 4 (S4) 11.11